Anzupgo (delgocitinib) / Japan Tobacco, LEO Pharma, Rohto Pharma - LARVOL DELTA

Topical pan-JAK inhibition in early mycosis fungoides: successful clinical response with delgocitinib - Clinical observation in the context of limited prospective evidence for topical application (ADO 2026) - No abstract available

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Topical pan-JAK inhibition in early mycosis fungoides: successful clinical response with delgocitinib - Clinical observation in the context of limited prospective evidence for topical application (ADO 2026) - No abstract available

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Rapid improvement in signs and symptoms with topical delgocitinib cream 20 mg/g in mixed atopic and irritant chronic hand eczema: a case report (EADV 2026) - No abstract available

Case report • Clinical • Contact Dermatitis • Dermatology • Immunology

Topical pan-JAK inhibition with delgocitinib 20mg/g cream in inflammatory diseases of the nails: a real-life case series (EADV 2026) - No abstract available

Clinical • Inflammation

Comprehensive Assessment of Skin Barrier Dysfunction in Chronic Hand Eczema in Patients Eligible for Delgocitinib: A Non-Invasive Comparative Study (EADV 2026) - No abstract available

Clinical • Non-invasive • Contact Dermatitis • Dermatology • Immunology

Evaluation of delgocitinib cream in chronic hand eczema: Early Real-World Experience (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Contact Dermatitis • Dermatology • Immunology

Treating successfully and keeping long-term remission in a patient with chronic hand eczema using delgocitinib (EADV 2026) - No abstract available

Clinical • Contact Dermatitis • Dermatology • Immunology

Delgocitinib cream provides rapid improvements in itch and pain symptoms in adolescents with moderate to severe chronic hand eczema: Results from DELTA TEEN (EADV 2026) - No abstract available

Contact Dermatitis • Dermatology • Immunology • Pain

Health-Related Quality of Life and work productivity improvements with topical delgocitinib vs oral alitretinoin in Chronic Hand Eczema: phase 3 DELTA FORCE results (EADV 2026) - No abstract available

Clinical • HEOR • P3 data • Contact Dermatitis • Dermatology • Immunology

Real-world effectiveness of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema: interim analysis after 8 weeks of treatment in the German REACHED study (EADV 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Contact Dermatitis • Dermatology • Immunology

Real-world effectiveness of topical delgocitinib in chronic hand eczema: a case series (EADV 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Contact Dermatitis • Dermatology • Immunology

Rapid Improvement with Topical Delgocitinib in Severe Refractory Atopic Dermatitis: A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Sustained Health-related Quality of Life improvements with delgocitinib 20 mg/g cream in Chronic Hand Eczema – results from the phase 3 open-label extension DELTA 3 trial (EADV 2026) - No abstract available

Clinical • HEOR • P3 data • Contact Dermatitis • Dermatology • Immunology

Delgocitinib cream reduces patient-reported disease severity in adults with moderate to severe Chronic Hand Eczema: pooled analysis of the Phase 3 DELTA 1 and DELTA 2 trials (EADV 2026) - No abstract available

P3 data • Retrospective data • Contact Dermatitis • Dermatology • Immunology

Hand eczema and its subtypes (EADV 2026) - "Finally, a stepped-care management approach will be outlined, from prevention and patient education to topical therapy (topical corticosteroids and calcineurin inhibitors), before advancing to therapies for refractory cases (phototherapy, alitretinoin, oral corticosteroids, cyclosporin, azathioprine, methotrexate, acitretin) and the topical pan-JAK inhibitor delgocitinib. Investigative work-up and exposure identification: participants will focus on patient history and diagnostic tools (patch testing, prick testing) to detect relevant triggers. Application of therapeutic algorithm: attendees will master a stepwise treatment protocol, progressing from basic therapy (emollients / skin care, exposure reduction) to topical and systemic therapy, focusing on treatment choice through clinical cases and gaining confidence of using targeted therapies like delgocitinib."

Contact Dermatitis • Dental Disorders • Dermatology • Immunology • Urticaria

Treatment with delgocitinib cream improves health-related quality of life in adolescents with moderate to severe chronic hand eczema: Results from DELTA TEEN; a randomized, double-blind, vehicle-controlled phase 3 trial (EADV 2026) - No abstract available

Clinical • HEOR • P3 data • Contact Dermatitis • Dermatology • Immunology

LEO Pharma receives positive CHMP opinion recommending Anzupgo (delgocitinib) cream for adolescents with moderate to severe chronic hand eczema in the EU (LEO Pharma Press Release) - "The CHMP opinion is supported by results from DELTA TEEN, a 16-week, phase 3, randomized, double-blind, vehicle-controlled, parallel-group, multi-site trial evaluating twice-daily applications of Anzupgo compared with cream vehicle in adolescents aged 12 to 17 years with moderate to severe chronic hand eczema for whom topical corticosteroids are inadequate or inappropriate."

CHMP • Dermatology

DelVito: Topical Delgocitinib for Facial Vitiligo (clinicaltrials.gov) - P2 | N=12 | Active, not recruiting | Sponsor: Lone Skov

New P2 trial • Dermatology • Immunology • Vitiligo

Leo Pharma's 'ANZUPGO (ingredient name delgocitinib)'…[was] also recognized as appropriate for coverage for the treatment of chronic hand eczema (Chosun Biz)

Reimbursement • Atopic Dermatitis

Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015-2025). (PubMed, J Clin Pract Res) - "Pruritus and alopecia areata (AA) were the most frequently co-occurring keywords alongside atopic dermatitis, while delgocitinib and abrocitinib were the most frequently investigated JAK inhibitors. Janus kinase (JAK) inhibitors represent one of the most effective and trending therapeutic classes in AD. These agents are not only highly effective for AD but also show promising efficacy in other dermatologic conditions, such as AA."

Journal • Alopecia • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Occupational Contact Dermatitis in the Post-COVID Era: From Barrier Dysfunction and Microbiome Dysbiosis to Prevention and Precision Management. (PubMed, J Clin Med) - "We summarise recent therapeutic advances, including topical delgocitinib, and situate the field within the World Health Organisation's 2025 recognition of skin diseases as a global public health priority. Established evidence and hypotheses are kept separate throughout: we additionally advance, explicitly as a conjecture rather than as a demonstrated mechanism, a conceptual trans-kingdom dialogue model in which protease-generated LL-37 fragments may modulate staphylococcal quorum sensing, and each step of that model is labelled according to whether the supporting evidence is direct, extrapolated, or as yet untested. We argue that the prevention failure is less one of biology than of trial design and measurement, and outline the research needed to close the gap."

Journal • Review • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease

Delgocitinib 20 mg/g cream for the treatment of lichen planopilaris: A case report. (PubMed, JAAD Case Rep) - No abstract available

Journal • Alopecia • Lichen Planus

Topical JAK-Inhibition of Early-Stage CTCL (clinicaltrials.gov) - P2 | N=15 | Not yet recruiting | Sponsor: Aarhus University Hospital

New P2 trial • Contact Dermatitis • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

High-salt microenvironment worsens the progression of atopic dermatitis via activating the SGK-1-mTOR pathway in keratinocytes. (PubMed, Genes Dis) - "Moreover, in combination with the JAK inhibitor delgocitinib, GSK 650394 exhibits a synergistic effect in ameliorating AD-like symptoms in vivo. Taken together, our findings demonstrate that the high-salt microenvironment promotes the development of AD by activating the SGK-1-mTOR pathway in keratinocytes, suggesting that an SGK-1 inhibitor could potentially serve as a drug to alleviate AD-like symptoms."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Novel nonsteroidal topical therapies for pediatric atopic dermatitis: a systematic review and network meta-analysis of randomized controlled trials. (PubMed, Front Immunol) - "Most active regimens improved IGA-TS versus vehicle, except tapinarof 0.5% once daily...Delgocitinib 0.5% twice daily ranked highest for IGA-TS and EASI-75, whereas difamilast 1% twice daily ranked highest for EASI-90...Further head-to-head, long-term, and age-stratified trials are needed. https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420261400624."

Clinical • Journal • Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics